These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 21215165)

  • 41. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
    Sun LX; Wu Y; Han HQ; Wang QH
    Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma].
    Zhang J; Li YH; Cui AR; Wang JL; Cheng JX; Wang SJ
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):905-9. PubMed ID: 19173990
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
    Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
    Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Recent advances on ovarian epithelial cancer: definition, subtypes and pathologic features].
    Guo DH; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):624-8. PubMed ID: 24314254
    [No Abstract]   [Full Text] [Related]  

  • 46. [Lymphatic metastasis and VEGF-C expression in ovarian epithelial tumors].
    Ding MX; Li JC; Tang XH
    Shi Yan Sheng Wu Xue Bao; 2003 Dec; 36(6):445-52. PubMed ID: 14724935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
    Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
    Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
    Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
    Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance].
    Shao SL; Cai Y; Wang QH; Yan LJ; Zhao XY; Wang LX
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):697-700. PubMed ID: 18246802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor].
    Zhang WY; Pan Y; Zhu LR; Zhang JZ; Zhang M; Feng K; Zhou L; Yu L; Zhang XM; Ng SW
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(42):2988-91. PubMed ID: 16324386
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
    Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
    Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
    Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
    Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
    Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
    Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
    [TBL] [Abstract][Full Text] [Related]  

  • 55. u-PA expression in benign, borderline and malignant ovarian tumors.
    Kiziridou AD; Toliou T; Stefanou D; Agnantis N
    Anticancer Res; 2002; 22(2A):985-90. PubMed ID: 12014682
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Application Value of HNF-1β Transcription Factor in the Diagnosis of Ovarian Clear Cell Carcinoma.
    Huang W; Cheng X; Ji J; Zhang J; Li Q
    Int J Gynecol Pathol; 2016 Jan; 35(1):66-71. PubMed ID: 26166716
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
    Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
    Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
    Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
    Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
    Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.